Performance status-1 - Slightly symptomatic - Page 15 of 19 Posts on Medivizor
Navigation Menu

Performance status-1 – Slightly symptomatic Posts on Medivizor

Phase II clinical trial testing the safety and efficacy of adding entinostat to exemestane therapy in hormone-resistant breast cancer patients

Phase II clinical trial testing the safety and efficacy of adding entinostat to exemestane therapy in hormone-resistant breast cancer patients

Posted by on Jun 5, 2013 in Breast cancer | 0 comments

In a nutshell This phase II clinical trial tested whether a new drug, entinostat, can work in concert with exemestane (a hormone therapy drug), to fight breast cancer that no longer responds to hormone therapy alone. Some background Some breast cancers need estrogen (a female sex hormone) to grow. These breast cancer cells respond to estrogen via...

Read More

Phase II clinical trial evaluating the effects of anti-inflammatory drug celecoxib as treatment for breast cancer patients

Phase II clinical trial evaluating the effects of anti-inflammatory drug celecoxib as treatment for breast cancer patients

Posted by on Jun 1, 2013 in Breast cancer | 0 comments

In a nutshell This phase II clinical trial evaluated the effect of the drug celecoxib (Celebrex) as treatment for patients with breast cancer.  Some background Inflammation is one of the body's natural responses to injury and may play a role in cancer formation. Inflammation is controlled in part by a type of hormone produced by cells...

Read More

Does breast cancer type and hormone status influence the efficacy of hormone therapy in breast cancer patients?

Posted by on Jun 1, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated the efficacy of hormone therapy in patients with two types of breast cancer, invasive ductal breast carcinomas (IDC) and invasive lobular breast carcinomas (ILC) based on hormonal status.  Some background Breasts are made up of lobules (milk-producing glands) and ducts (tubes that carry the milk to the...

Read More

Phase 3 clinical trial evaluating the safety and efficacy of adding docetaxel to doxorubicin and cyclophosphamide chemotherapy in node positive breast cancer patients

Phase 3 clinical trial evaluating the safety and efficacy of adding docetaxel to doxorubicin and cyclophosphamide chemotherapy in node positive breast cancer patients

Posted by on May 30, 2013 in Breast cancer | 0 comments

In a nutshell In this phase 3 clinical trial, two types of adjuvant (a treatment given in addition to a main treatment) chemotherapy regimens were compared in women with node positive breast cancer after surgery to remove the cancer. These were the combination of docetaxel (Taxotere), doxorubicin and cyclophosphamide (TDC) or the combination of...

Read More

Evaluating the benefits of histamine type 2 receptor antagonists in colorectal cancer patients treated with surgery

Evaluating the benefits of histamine type 2 receptor antagonists in colorectal cancer patients treated with surgery

Posted by on May 28, 2013 in Colorectal cancer | 0 comments

In a nutshell The present review evaluated the benefits of histamine type 2 receptor antagonists or H2RA (a type of drugs used for the treatment of stomach ulcers) before or after surgery in patients with colorectal cancer (CRC). Some background CRC is cancer in the large intestine. In the early stages (when it is confined to the bowel), CRC is...

Read More

Comparing the outcomes of laparoscopic versus open surgery in patients with colorectal cancer

Posted by on May 9, 2013 in Colorectal cancer | 0 comments

In a nutshell This study compared the short- and long-term outcomes of two types of surgery for patients with colorectal cancer (CRC): open surgery (OS) versus laparoscopic surgery (LS). LS led to less pain following surgery, shorter hospital stays, faster recovery times, and improved survival rates. Some background CRC is very common,...

Read More

Is early recurrence after surgery a poor predictor on survival in patients with colorectal cancer?

Is early recurrence after surgery a poor predictor on survival in patients with colorectal cancer?

Posted by on May 9, 2013 in Colorectal cancer | 0 comments

In a nutshell This study tested whether early recurrence in patients with colorectal cancer (CRC) treated with surgery can predict patients’ survival. The authors of the study found that early recurrence after surgery is associated with poorer survival in CRC patients. Some background Up to a half of CRC patients can develop a recurrence...

Read More

Can a scoring system called a nomogram help develop a treatment program that is individual to each patient?

Can a scoring system called a nomogram help develop a treatment program that is individual to each patient?

Posted by on May 3, 2013 in Colorectal cancer | 0 comments

In a nutshell This article is a short editorial describing how the use of a “nomogram” (a predictive tool based on a points system) could provide a doctor and patient with possible outcomes if different treatment options are selected. Some background The current method of choosing treatment for patients with rectal cancer is fairly...

Read More

Combination of Anastrozole and Fulvestrant therapy in hormone receptor positive metastatic breast cancer

Combination of Anastrozole and Fulvestrant therapy in hormone receptor positive metastatic breast cancer

Posted by on Apr 29, 2013 in Breast cancer | 0 comments

In a nutshell This study compared the effect of two regimens for hormone-positive, metastatic breast cancer on disease progression and survival: a combination of two drugs, namely anastrozole (Arimidex) and fulvestrant (Faslodex), versus anastrozole alone.  Some background Breast cancers often require estrogen (the female sex...

Read More

Robotic radiation treatment compared to radiofrequency ablation for the treatment of liver metastases from colorectal cancer

Robotic radiation treatment compared to radiofrequency ablation for the treatment of liver metastases from colorectal cancer

Posted by on Apr 21, 2013 in Colorectal cancer | 0 comments

In a nutshell This article compares the use of radiofrequency ablation (RFA) and a robotic method of treatment using directed radiation to liver metastases from colorectal cancer which have been deemed not suitable for surgical treatment.  The study shows robotic radiation treatment is safe and comparable to RFA, with a trend towards being better...

Read More

A potential new treatment for triple negative breast cancer: Blocking TGF-beta may improve the outcomes of chemotherapy

A potential new treatment for triple negative breast cancer: Blocking TGF-beta may improve the outcomes of chemotherapy

Posted by on Apr 21, 2013 in Breast cancer | 0 comments

In a nutshell This laboratory based study investigates the use of compounds which block TGF-β signalling in triple negative breast cancer cells.  They show that inhibiting this process prevents the development of paclitaxel resistance and the recurrence of cancers following paclitaxel treatment.  Some background Triple negative...

Read More

The link between tumor response 8 weeks into the treatment and overall survival in metastatic breast cancer patients treated with first-line chemotherapy

The link between tumor response 8 weeks into the treatment and overall survival in metastatic breast cancer patients treated with first-line chemotherapy

Posted by on Apr 21, 2013 in Breast cancer | 0 comments

In a nutshell The aim of this article was to determine if the initial shrinking of tumors due to combined chemotherapy is correlated with overall survival (OS) in patients with metastatic breast cancer (MBC – spread to other organs). Some background OS (survival at the end of the treatment) is the best parameter to evaluate treatment...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2025 Medivizor